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Staphylococcus epidermidis is one of the most important opportunistic pathogens in
nosocomial infections. The main pathogenicity associated with S. epidermidis involves
the formation of biofilms on implanted medical devices, biofilms dramatically decrease
the efficacy of conventional antibiotics and the host immune system. This emphasizes
the urgent need for designing novel anti-staphylococcal biofilm agents. Based on the
findings that compound 5, targeting the histidine kinase domain of S. epidermidis YycG,
possessed bactericidal activity against staphylococci, 39 derivatives of compound 5
with intact thiazolopyrimidinone core structures were newly designed, 7 derivatives were
further screened to explore their anti-bacterial and anti-biofilm activities. The seven
derivatives strongly inhibited the growth of S. epidermidis and Staphylococcus aureus in
the minimal inhibitory concentration range of 1.56–6.25 µM. All the derivatives reduced
the proportion of viable cells in mature biofilms. They all displayed low cytotoxicity on
mammalian cells and were not hemolytic to human erythrocytes. The biofilm inhibition
activities of four derivatives (H5-32, H5-33, H5-34, and H5-35) were further investigated
under shearing forces, they all led to significant decreases in the biofilm formation of
S. epidermidis. These results were suggestive that the seven derivatives of compound
5 have the potential to be developed into agents for eradicating biofilm-associated
infections.
Keywords: Staphylococcus epidermidis, histidine kinase YycG, minimal inhibitory concentration, minimal
bactericidal concentration, anti-biofilm activity
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INTRODUCTION
Staphylococcus epidermidis is one of the most important
opportunistic pathogens in nosocomial infections, in particular,
it is the leading cause of biofilm infections related to implanted
medical devices (Otto, 2009). Once a biofilm has been established
on these devices, it is difficult to eradicate because the bacteria
in a biofilm are protected from attack by the host immune
system and are generally much more resistant to antibiotics
or biocides than their planktonic counterparts (Høiby et al.,
2011). A possible mechanism underlying this resistance is
that biofilm-encased bacteria might restrict the diffusion of
antibiotics due to interactions with the exopolysaccharide matrix
(Lewis, 2001). Currently, the effective treatment for such biofilm
infections is to remove or replace the implanted devices,
resulting in substantial healthcare costs (Vuong and Otto, 2002).
Biofilms are also associated with the emergence and spread of
antimicrobial resistance (Römling and Balsalobre, 2012; Savage
et al., 2013). In addition, with the excessive use of antibiotics
in hospitals, there have been more and more reports of multi-
drug resistance in staphylococci, resulting in most of the available
agents having a limited efficacy in treating serious infections
caused by staphylococci, such as prosthetic valve endocarditis
and blood infections (Raad et al., 1998; Ventola, 2015). New
strategies for combating biofilm infections, therefore, have
become challenging and are attracting considerable scientific
attention (Sadekuzzaman et al., 2015). In the past few decades,
the development of bacterial genomics, bioinformatics, and
gene manipulation have brought about new opportunities for
discovering many novel protein targets for anti-bacterial agents
(Moir et al., 1999; Silver, 2011).
Two-component systems (TCSs) are important regulators in
most bacteria for cell adaption to environmental conditions
(Stock et al., 2000; Bijlsma and Groisman, 2003). A TCS
usually consists of a histidine kinase (HK) and a response
regulator (Stock et al., 2000). TCSs have no human homologs or
structurally similar proteins (Bem et al., 2015); thus, they have
attracted increasing attention as potential anti-bacterial targets
(Macielag and Goldschmidt, 2000). Among TCSs, YycG/YycF
(also known as WalK/WalR) is essential in low G+C Gram-
positive bacteria, such as Bacillus subtilis, Enterococcus faecalis,
Staphylococcus aureus, and Streptococcus pneumoniae (Fabret
and Hoch, 1998; Martin et al., 1999; Throup et al., 2000;
Hancock and Perego, 2002). It has been shown that inhibitors
acting directly against YycG or YycF (WalR) have bactericidal
effects and are active against an array of clinically important
Gram-positive pathogens (Watanabe et al., 2003; Gotoh et al.,
2010; Okada et al., 2010). Using a structure-based virtual
screening approach, we have found two leading compounds
(compound 2 and compound 5) targeting YycG that possess not
only bactericidal but also potent anti-biofilm activities against
staphylococci (Qin et al., 2006; Huang et al., 2012; Liu et al.,
2014).
To improve the anti-bacterial activities and reduce
the toxicity to mammalian cells of leading compound
5, 39 derivatives of it were designed and synthesized by
introducing different functional groups, while keeping the
thiazolopyrimidinone core structure intact (Zhao et al.,
2014). Based on inhibitory activities against S. epidermidis,
seven more-potent derivatives of compound 5 were screened
out for further exploration of their bactericidal activity
and anti-biofilm activity, as well as YycG phosphorylation
inhibiting activity and cytotoxicity. The seven derivatives all
displayed a strong bactericidal effect with low cytotoxicity
on mammalian cells and were not hemolytic to human
erythrocytes.
MATERIALS AND METHODS
Bacterial Strains, Culture Media, and
Antibiotics
S. epidermidis ATCC 12228 (biofilm negative), S. epidermidis
ATCC 35984 (biofilm positive), S. aureus ATCC 49230 and
Escherichia coli ATCC 25922 were used in this study. Six clinical
methicillin-resistant S. aureus (MRSA) isolates were collected
from the Department of Clinical Laboratory, Shanghai General
Hospital, School of Medicine, Shanghai Jiaotong University,
China. Staphylococcal strains were grown in tryptic soy broth
(TSB; Oxoid Ltd., Basingstoke, England), and E. coli strains
were grown in Luria-Bertani broth medium. Mueller-Hinton
broth (MHB; Oxoid Ltd., Basingstoke, England) was used for
antimicrobial susceptibility testing. Vancomycin and ampicillin
were obtained from the Sigma Chemical Co. (St Louis, MO,
USA).
Synthesis of the Derivatives of
Compound 5
All the 39 derivatives of compound 5 were synthesized
by introducing various chemical groups, while keeping
the thiazolopyrimidinone core structure intact, and were
provided by Nanjing University of Technology, China, and
the Department of Natural Products Chemistry, School of
Pharmacy, Fudan University, China. Based on the thiazolidione
core structure of compound 5 {5-benzo [1,3] dioxol-5-yl-2-
[5-(3-carboxy-phenyl)-furan-2-ylmethylene]-3-oxo-7-phenyl-
2, 3 -dihydro-5H-thiazolo [3,2-a] pyrimidine-6-carboxylic} acid
ethyl ester, seven derivatives were designed and synthesized
by modifying the functional groups through cyclization,
aldol condensation, substitution, and hydrolyzation reactions:
H5-23, 2-{5-(3-carboxy-phenyl)-furan-2-ylmethylene]-5-(4
-chloro-phenyl)-3-oxo-7-phenyl-2, 3-di-hydro-5H-thiazolo
[3,2-a] pyrimidine-6-carboxylic acid ethyl ester; H5-24, 3-{5
-[5-(4-methoxy-phenyl)-3-oxo-7-phenyl-5H-thiazolo[3,2-a]
pyrimidin-2-ylidenemethyl]-furan-2-yl}-benzoic acid; H5-
25, 3-{5-[5-(4-chloro-phenyl)-3-oxo-7-phenyl-5H-thiazolo
[3,2-a] pyrimidin-2-ylidenemethyl]-furan-2-yl}-benzoic acid;
H5-32: 2-[5-(3-carboxy-phenyl)-furan-2-ylmethylene]-5-(4-
fluoro- phenyl)-3-oxo-7-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]
pyrimidine-6-carboxylic acid ethyl ester; H5-33, 3-{5-[5-(4-
fluoro-phenyl)-3-oxo-7-phenyl-5H-thiazolo [3,2-a] pyrimidin-
2-ylidenemethyl]-furan-2-yl}-benzoic acid; H5-34, 2-[5-(4-
carboxy-phenyl)-furan-2-ylmethylene]-5-(4-chloro-phenyl)-3-
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oxo- 7-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-
carboxylic acid ethyl ester; H5-35, 2-[5-(4-carboxy-phenyl)-
furan-2-ylmethylene]-5-(4-fluoro-phenyl)-3-oxo-7-phenyl-2,3-
dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic acid ethyl
ester. The structural formulas of the derivatives are listed in
Figure 1. Stock solutions of 200 mM derivatives were prepared
in dimethylsulfoxide (DMSO; AMRESCO, USA) and stored at
−80◦C.
Inhibition Assay for YycG′
Autophosphorylation
The construction of the recombinant plasmid pET28a-YycG′
(containing the HATPase_c and HisKA domains of YycG)
has been previously described (Liu et al., 2014). After being
used to transform E. coli strain BL21(DE3), this recombinant
plasmid was induced to express YycG′ protein by 0.4 mM
isopropyl-1-thio-β-D-galactopyranoside at 21◦C for 12 h. Then,
the bacterial cells were disrupted by sonication and centrifuged,
the supernatant was purified by Ni–NTA agarose (Qiagen, Los
Angeles, CA, USA). The inhibitory activities of the compound
5 derivatives on the ATPase activity of the YycG′ protein were
measured using the Kinase-GloTM Luminescent Kinase Assay
(Promega, Madison, WI, USA). Briefly, 2 µg purified YycG′
protein was pre-incubated with a series of dilutions of the
derivatives in reaction buffer [40 mM Tris (pH 7.5), 20 mM
MgCl2 and 0.1 mg/ml BSA] at room temperature for 30 min,
4 µM ATP was added and incubated for 30 min at room
temperature, then Kinase-GloTM Reagent was added to detect
the remaining amount of ATP, as reflected by luminescence
intensity (RLU). In parallel, YycG′ protein with no addition of
the derivatives was used as the control and ATP only was used as
a blank. The rate of inhibition of protein phosphorylation (Rp)
by the derivatives was calculated by the following equation:
Rp=
RLU(YycG′ + derivative+ ATP+ Kinase− GloTM)
−RLU(YycG′ + ATP+ Kinase− GloTM)
RLU(ATP+ Kinase− GloTM)
−RLU(YycG′ + ATP+ Kinase− GloTM)
×100
IC50 (the concentration resulting in 50% inhibition of YycG
′
protein autophosphorylation) was obtained by using Origin v7.0
software (OriginLab, Northampton, USA).
Minimal Inhibitory Concentration (MIC) and Minimal
Bactericidal Concentration (MBC) Assays of the Derivatives
The MIC assays of the derivatives of compound 5 against
S. epidermidis, S. aureus, MRSA and E. coli were performed
by using the methods described previously by Wiegand et al.
(2008). In brief, two-fold serial dilutions of the derivatives were
FIGURE 1 | Chemical structures of seven compound 5 derivatives.
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prepared in tubes containing 4 mL MHB medium, yielding final
concentrations from 200 to 0.78 µM. Bacterial cultures were
grown overnight and adjusted so that the bacterial suspension
turbidity was equivalent to a 0.5 McFarland standard (∼1 × 108
CFU/mL) and further diluted to 1:200 into MHB medium. The
contents in the tubes were mixed thoroughly and incubated at
37◦C with shaking at 220 rpm for 16–20 h. The MIC endpoint
was defined as the lowest concentration at which there was no
visible growth in the tubes. The MBC values were assessed by
plating 100 µL samples from each negative (no visible bacterial
growth) culture tube from the MIC assays onto blank MHB agar
plates. After incubation at 37◦C for 24 h, the bacterial colonies
on the plates were counted. The MBC was the concentration at
which a 99.9% reduction of the original inoculum was observed
(Pridmore et al., 2011). In this assay, all the experiments were
performed three times.
Time-Killing Assays of the Derivatives
against S. epidermidis
Suspensions of S. epidermidis (1 × 107 CFU/mL) were prepared
and separately treated with the derivatives of compound 5 or
vancomycin at concentrations of 4×MIC in fresh MHB. Time-
kill experiments were performed at 37◦C with shaking at 220
rpm under aerobic conditions. Aliquots (1 mL) were removed
from the culture medium at different time points (0, 1, 3, 5, 8,
and 24 h), serially diluted and 100 µL of each of the dilutions
plated out onto tryptic soy agar. After incubating at 37◦C for
24 h, emergent bacterial colonies were counted, and the activity
of the derivatives against fast-growing S. epidermidis cells was
determined by plotting log10 colony counts (CFU/mL) against
time. Bactericidal activity was defined as a 3-log10 decrease in
CFU/mL. This assay was performed in triplicate and similar
results were obtained.
Anti-biofilm Activity Detection of the
Derivatives
Microtiter Plate Assays of S. epidermidis Biofilms
The biofilm-killing effect for immature (6 h old) biofilms was
determined in TSB using a semi-quantitative assay. An overnight
culture was diluted 1:200 into TSB medium with 0.25% glucose,
and incubated in polystyrene 96-well plates at 37◦C for 6
h. Biofilms were exposed to two-fold serial dilutions of the
derivatives, and the plates were incubated for another 18 h at
37◦C. Following the incubation and removal of non-adherent
cells with 200 µl of phosphate-buffered saline, adherent biofilms
were fixed with 95% methanol and stained with 2% (w/v) crystal
violet. Then, the wells were washed three times with sterile
distilled water and the plates were air dried for 2 h. The optical
density of each well at 570 nm was determined using a 96-well
plate spectrophotometer (DTX880, Beckman Coulter, USA).
Determination of Cell Viability in Mature Biofilms by
Confocal Laser Scanning Microscope (CLSM)
The effect of the derivatives on cell viability in mature biofilms
(24 h old) was determined using the Live/Dead Bacterial
Viability method (Live/Dead BacLight, Molecular Probes, USA).
Individual wells of cell-culture dishes (WPI, USA) were filled
with diluted culture, after incubation at 37◦C for 24 h, the
planktonic cells were removed and fresh TSB containing the
derivatives at concentrations of 4×MICwas added and incubated
at 37◦C for another 16 h. The mature biofilms were stained
with SYTO 9 and propidium iodide at room temperature for
15 min, following gentle washing of the dishes with normal
saline, and were observed under a Leica TCS SP5 CLSM with
a 63 × 1.4-NA oil-immersion objective. Further, image analysis
was performed using IMARIS 7.0.0 software (Bitplane). The
fluorescence quantities of biofilm were determined using Image
J software. This assay was performed in triplicate and similar
results were obtained.
Flow-Based Biofilm Inhibition Assays by BioFlux
The microfluidic channels of BioFlux 48-well plates (Fluxion
Biosciences, South San Francisco, CA, USA) were primed with
pre-warmed (37◦C) TSB medium from the outlet well at a shear
setting of 2 dyn/cm2 for 10 min. Overnight bacterial culture of S.
epidermidis ATCC 35984 was subcultured to mid-log phase and
then diluted 1:200 in MHB medium, bacteria were seeded from
the outlet well into the channel and viewing window at a shear
setting of 2 dyn/cm2 for 3 s. After 1 h incubation for bacteria
attachment at 37◦C, fresh TSBmedium containing 2×MIC of the
derivatives was flowed from the inlet well at a shear setting of 0.15
dyn/cm2. Growth of the biofilms was monitored for up to 16 h.
Images of different stages were automatically acquired at 10 min
intervals with bright-field illumination.
Cytotoxicity and Erythrocyte Hemolysis
Assays
A Cell Proliferation Kit I (MTT; Roche, Indianapolis, USA)
was used to detect the cytotoxicity of the derivatives against
Vero cells. Vero cells were added to 96-well microtiter plates
at a concentration of 5 × 104 cells/well in 100 µL of culture
medium. After 24 h, culture medium was replaced by 100 µL
serial dilutions of the derivatives (0.78–100 µM) and the cells
were incubated for 4 h in an atmosphere of 5% CO2, then 10
µL of the MTT stock solution was added to each well and the
plate returned to the 37◦C incubator for 4 h. Subsequent to the
incubation, the purple formazan salts were dissolved in DMSO,
and the absorbance of each well was measured at wavelengths
of 595 nm (test) and 655 nm (reference). Cells treated with
the solvent (0.1% DMSO) were used as a blank control. The
concentration of the derivatives that produced a 50% cytotoxicity
effect on Vero cells (CC50) was calculated using Origin v8.0
software (Origin Lab, Northampton, USA).
Hemolytic activities of the derivatives were measured on
healthy human erythrocytes. A pure suspension of erythrocytes
was obtained by washing a blood sample with sterile 0.9% NaCl
saline solution. Erythrocytes were resuspended in normal saline
to give a 5% solution, then treated with MIC, 4×MIC or 200 µM
of the derivatives for 1 h at 37◦C in 96-well microtiter plates.
After the incubation and centrifugation at 1,000 g for 10 min,
supernatants were transferred to another sterile plate and the
absorbance at 570 nm was measured on a spectrophotometric
microplate reader. A positive control (100% hemolysis)
and a negative control (0% hemolysis) were achieved by
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incubating with 1% Triton-X 100 and 0.1% DMSO, respectively.
Each assay was performed in triplicate and repeated three
times.
Statistics
Experiments were performed in triplicate and repeated at least
three times. One-way analysis of variance (ANOVA) was utilized
for data comparison. Differences in means were considered
significant when P < 0.05.
RESULTS
Inhibition of the YycG′ Protein Atpase
Activity
To confirm the interaction of the potential YycG inhibitors with
their putative target protein, recombinant YycG′ was expressed
and purified (Liu et al., 2014). The enzymatic inhibitory effects of
the derivatives on YycG′ kinase activity were determined by using
a Kinase-GloTM Luminescent Kinase assay. The seven derivatives
displayed dose-dependent inhibition of the autophosphorylation
activity of YycG′. At the concentration 100 µM, H5-23, H5-24,
H5-25, H5-32, H5-33, H5-34, and H5-35 inhibited the enzymatic
activity of 2 µg YycG′ protein in the presence of 4 µM ATP by
64.78, 49.92, 51.42, 55.61, 77.04, 80.72, and 63.94%, respectively.
The IC50 values of the seven derivatives were 77.18, 82.16, 80.23,
83.91, 64.90, 61.94, and 78.19 µM, respectively (Table 1).
Antimicrobial Activity of the Derivatives
against Planktonic Bacteria
We determined the MIC values of the derivatives by using
a standard tube-dilution assay. The seven derivatives (H5-23,
H5-24, H5-25, H5-32, H5-33, H5-34, and H5-35) inhibited
bacterial growth of S. epidermidis ATCC 35984, and the MIC
values were 1.56, 1.56, 1.56, 3.13, 3.13, 3.13, and 3.13 µM,
respectively. Furthermore, they showed similar anti-bacterial
activities against S. epidermidisATCC 12228 and S. aureusATCC
49230, whereas none of them showed anti-bacterial activity
on E. coli strain ATCC 25922, even at the concentration of
200 µM (Table 2). Subsequently, the bactericidal activities of
these derivatives against planktonic S. epidermidis ATCC 35984
cells were investigated. All seven derivatives showed bactericidal
activities, and the MBC values were 25, 50, 50, 100, 12.5, 25, and
12.5 µM (4× to 32×MIC), respectively (Table 1).
Activities of the Derivatives against
Fast-Growing S. epidermidis
We used a time-kill assay to determine the effectiveness of
the derivatives against fast-growing S. epidermidis cells. Four
TABLE 2 | Anti-Staphylococcus activities of seven derivatives of
compound 5.
Derivativesa MICb (µM)
S.epidermidis
ATCC35984
S.epidermidis
ATCC12228
S.aureus
ATCC49230
E.coli
ATCC29522c
Compound 5 6.25 6.25 6.25 >200
H5-23 1.56 1.56 1.56 >200
H5-24 1.56 1.56 1.56 >200
H5-25 1.56 1.56 1.56 >200
H5-32 3.13 6.25 3.13 >200
H5-33 3.13 3.13 3.13 >200
H5-34 3.13 3.13 3.13 >200
H5-35 3.13 3.13 6.25 >200
aStock solutions(200 mM) of the derivatives were prepared in DMSO.
bMIC of the derivatives was determined by macrodilution method of the CLSI of America.
cThe derivatives did not inhibit the growth of E. coli ATCC 25922, even at the highest
concentration used in the experiment.
TABLE 1 | Biological activities of seven derivatives of compound 5.
Derivativesa Molecular Formula MW MICb(µM) MBCb(µM) MBKCb (µM) ICc
50
(µM) CCd
50
(µM) Hemolysise (%)
At MIC 200 µM
Compound 5 C34H24N2O8S 620 6.25 25 50 N/D >200 0.31 ± 0.16 0.51 ± 0.06
H5-23 C33H23ClN2O6S 610 1.56 25 100 77.18 >200 0.27 ± 0.35 0.27 ± 0.01
H5-24 C31H22N2O5S 534 1.56 50 50 82.16 >200 0.17 ± 0.11 0.32 ± 0.05
H5-25 C30H19ClN2O4S 538 1.56 50 100 80.23 >200 0.27 ±0.01 0.39 ± 0.09
H5-32 C33H23FN2O6S 594 3.13 100 25 83.91 >200 0.15 ± 0.05 0.24 ± 0.05
H5-33 C30H19FN2O4S 522 3.13 12.5 12.5 64.90 >200 0.15 ± 0.06 0.32 ± 0.05
H5-34 C33H23ClN2O6S 610 3.13 25 25 61.94 >200 0.22 ± 0.57 0.19 ± 0.01
H5-35 C33H23FN2O6S 594 3.13 12.5 25 78.19 >200 0.17 ± 0.05 0.27 ± 0.10
MW, molecular weight; N/D, not determined.
aStock solutions (200 mM) of the derivatives were prepared in DMSO.
bMIC,MBC, andMBKC represent theminimal inhibitory concentration, minimal bactericidal concentration andminimal biofilm-killing concentration of the derivatives against S.epidermidis
ATCC 35984.
c IC50 represents half maximal inhibitory concentration of the derivatives, which inhibit half of the autophosphorylation of recombinant YycG
′ determined by the Kinase-GloTM Luminescent
Kinase Assay kit.
dCC50 represents the derivative concentration that produces 50% cytotoxicity effects on Vero cells. The highest concentration tested in the experiment was 200 µM.
eHemolytic activities of the derivatives were detected on healthy human erythrocytes at their MICs and 200µM against S epidermidis ATCC 35984.
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derivatives (H5-32, H5-33, H5-34, and H5-35) as well as
vancomycin at the concentration of 4×MIC were separately
added into fresh MHB cultures. The starting bacterial inoculum
was ∼1 × 107 CFU/mL. Untreated control bacterial cells grew
fast (increasing >3 log10 CFU/mL over a 24 h period). All of
the derivatives exhibited bactericidal activity in growing cultures
of S. epidermidis with a 3-log reduction in CFU/mL within 1 h,
whilst vancomycin only caused a decrease of ∼1 log after 1 h (P
< 0.001), and exhibited a more protracted bactericidal activity
than the four derivatives as >5 h were required to achieve a
bactericidal effect (Figure 2).
Activities of the Derivatives against Young
Biofilms
Effects of the derivatives on young biofilms of S. epidermidis
ATCC 35984 were determined in 96-well polystyrene microtiter
plates. After inoculation, the bacteria in the wells of the plates
were incubated for 6 h to form immature (young) biofilms, and
then two-fold serial dilutions of the derivatives were added and
incubated for another 18 h. Young biofilm treated with 0.1%
DMSO served as a negative control. The minimal biofilm-killing
concentration ranged from 12.5 to 100 µM. The derivatives
H5-32, H5-33, H5-34, and H5-35 showed stronger biofilm-
killing effects at the concentrations of 12.5 or 25 µM than
other derivatives (Table 1); therefore, these four derivatives were
further investigated for inhibition of biofilm formation activities
with a BioFlux 1,000.
After pumping bacteria into the channel of the BioFlux 1,000
and incubating for 1 h, fresh TSB medium containing 2×MIC
FIGURE 2 | Time-kill curves against S. epidermidis ATCC 35984. The
bacteria were separately treated with the derivatives of compound 5 or
vancomycin at concentrations of 4×MIC in fresh MHB. Aliquots (1 mL) were
removed from the culture medium at different time points (0, 1, 3, 5, 8, and 24
h), serially diluted, plated out 100 µL of each of the dilutions onto tryptic soy
agar. Viability was counted at the indicated time points by serial dilution
plating, the activity of the derivatives against fast-growing S. epidermidis cells
was determined by plotting log10 colony counts (CFU/mL) against time. Values
are the mean of independent tests performed in triplicate with error bars.
of the derivatives was separately flowed from the inlet well at
a shear setting of 0.15 dyn/cm2, and then biofilm formation
was monitored for another 16 h. In the channels treated with
the derivatives of compound 5 (H5-32, H5-33, H5-34, and H5-
35) there was a significant decrease in the biofilm formation
of S. epidermidis 35984. When grown in the absence of the
inhibitors, bacteria showed initial attachment (1 h), microcolony
formation (3 h), biofilm development (8 h), and firmly attached
to the microfluidic flow channel and formed a robust biofilm (16
h) (Figure 3; also see the kinetic movies of biofilm formation,
Supplementary Videos 1–5 in the supplemental material).
Activity of the Derivatives against Mature
Biofilms
The effects of the derivatives on cell viability inmature biofilms of
S. epidermidis were detected by a CLSM with Live/Dead staining.
The inoculated bacteria in the wells of plates were incubated for
24 h to form mature biofilms. All of the derivatives reduced the
proportion of viable cells in mature biofilms in varying degrees,
especially H5-23, H5-24, H5-33, and H5-35 (85.7, 77.5, 88.4, and
71.7%, respectively), as shown in Figure 4. As has been previously
described (Liu et al., 2014), vancomycin (128 µg/mL) showed
little effect on the bacterial viability in the biofilms, reduced living
cells in mature biofilm only by 11.4%.
FIGURE 3 | Inhibitory effects of the derivatives on biofilm formation of
S. epidermidis under flowing condition. Overnight bacterial cultures of S.
epidermidis ATCC 35984 were subcultured to the mid-log phase and then
diluted 1:200 in MHB medium, bacteria were seeded from the outlet well into
the channel and viewing window at a shear setting of 2 dyn/cm2 for 3 s. After
1 h incubation for bacteria attachment at 37◦C, the fresh TSB medium
containing 2×MIC of the derivatives was flowed from the inlet well at a shear
setting of 0.15 dyn/cm2. Bright-field images depicting biofilm development
after 16 h were captured at 10 times the original magnification.
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FIGURE 4 | Effects of the derivatives on mature biofilms of S. epidermidis ATCC 35984 was grown in cell-culture dishes and incubated at 37◦C for 24
h, the planktonic cells were removed and fresh TSB containing the derivatives at concentrations of 4×MIC were added and incubated at 37◦C for
another 16 h. The mature biofilms were stained with SYTO 9 and propidium iodide and observed under a Leica TCS SP5 CLSM with a 63 × 1.4-NA oil-immersion
objective. Images of three-dimensional biofilm structure were performed using IMARIS 7.0.0 software based on CLSM data at ∼0.5 µm increments. Cells stained with
green fluorescence were viable and with red fluorescence were dead. The fluorescence quantities of biofilm were determined by using Image J software. Statistical
significance was determined using one-way ANOVA with respect to the control (only DMSO added). Data represents mean ± SD of three independent experiments.
Cytotoxicity and Hemolysis of the
Derivatives In vitro
The cytotoxicity of the derivatives against Vero cells (African
green monkey kidney epithelial cells) was assessed by using
the MTT assay. Cells treated with 0.1% DMSO were used
as a negative control. Compared with the control group, no
obvious cytotoxic effects of the derivatives against Vero cells
were detected, the CC50 values of the tested derivatives were all
higher than the highest concentration used in this study (200µM;
Table 1).
All the seven derivatives displayed no obvious hemolysis
on healthy human erythrocytes at MICs and even up to the
concentration of 200 µM (Table 1). As a positive control,
treatment with 1% Triton-X100 resulted in 100% hemolysis of
human erythrocytes, while no hemolysis was observed in cells
that were treated with 0.1% DMSO, as a negative control.
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DISCUSSION
S. epidermidis is the main cause of biomaterial-associated
infections. The most important virulence factors associated with
S. epidermidis are related to biofilm formation, whereas S. aureus
produces toxins and tissue-damaging exoenzymes (Vuong and
Otto, 2002). Biofilms on the inert surfaces of implanted medical
devices impair the penetration of antibiotics and impede the
host immune response, ultimately requiring surgical removal
of the infected biomaterial and subsequent replacement (Otto,
2009; Høiby et al., 2011). In this regard, effective chemical
agents for inhibition and eradication of biofilms are urgently
needed. With a structure-based virtual screening approach,
we have found two leading compounds (compound 2 and
compound 5) targeting YycG that not only were bactericidal,
but also possessed potent biofilm-killing activity against S.
epidermidis (Qin et al., 2006; Huang et al., 2012; Liu et al., 2014).
Compound 2 had a thiazolidione core structure, while compound
5 had a thiazolopyrimidinone core. A series of derivatives of
compound 2 have been synthesized and evaluated for their
anti-bacterial and anti-biofilm activities in our previous work
(Huang et al., 2012; Liu et al., 2014). In the present study, we
designed and synthesized a series of derivatives of compound
5 by introducing different functional groups, while keeping the
thiazolopyrimidinone core structure intact, to improve the anti-
bacterial and anti-biofilm activities (Zhao et al., 2014).
The YycG/YycF (also known as WalK/WalR) TCS was first
recognized in B. subtilis by Fabret and Fukuchi et al. and appears
to be essential (Fabret and Hoch, 1998; Fukuchi et al., 2000).
It is highly conserved and specific to low G+C Gram-positive
bacteria, such as B. subtilis, Streptococcus pneumoniae, S. aureus,
S. epidermidis and Listeria monocytogenes (Fabret and Hoch,
1998; Martin et al., 1999; Throup et al., 2000; Kallipolitis and
Ingmer, 2001; Qin et al., 2006). YycG/YycF plays major roles in
regulating cell-wall metabolism (Bisicchia et al., 2007; Dubrac
et al., 2008), cell viability and division (Fukuchi et al., 2000;
Bisicchia et al., 2007), virulence-factor expression (Ng et al.,
2005; Senadheera et al., 2005), lipid integrity (Mohedano et al.,
2005; Ng et al., 2005), exopolysaccharide biosynthesis and biofilm
formation (Senadheera et al., 2005; Shemesh et al., 2006; Ahn
and Burne, 2007). Because of its essential biological functions,
the YycFG TCS has been considered as an attractive target for
anti-infective therapeutics. It has been reported that inhibitors
targeting WalK (YycG), walkmycin B and aranorosinol B, had
anti-bacterial activity against S. aureus and B. subtilis in the
low MIC range (Watanabe et al., 2003; Okada et al., 2010).
Based on virtual screening, inhibitors targeting VicK (YycG)
that actively inhibited the growth of Streptococcus pneumoniae
were discovered by Li et al. (2009). Here, we mainly focused
on studying the anti-biofilm properties of the newly synthesized
compound 5 derivatives. By substituting different functional
groups, while keeping the core structure intact, 39 derivatives
of compound 5 were synthesized (Zhao et al., 2014). By testing
the anti-staphylococcal activities of the derivatives, seven of
them (H5-23, H5-24, H5-25, H5-32, H5-33, H5-34, and H5-35)
were shown to have more potent anti-bacterial and anti-biofilm
activities than leading compound 5. Additionally, four derivatives
(H5-32, H5-33, H5-34, and H5-35) exhibited antimicrobial
activities against six MSRA clinical isolates (MICs from 3.13 to
6.25 µM), and produced a ≥99.9% reduction in the bacterial cell
count at concentrations of 8- to 32-fold higher than their MICs
(see Supplementary Table 1 in the supplemental material). We
also determined the antimicrobial activities of the four derivatives
(H5-32, H5-33, H5-34, and H5-35) against Enterococcus faecalis
OG1RF (from the American Type Culture Collection) by using
a standard tube-dilution assay. The four derivatives displayed
anti-bacterial activities on Enterococcus faecalisOG1RF. This was
suggestive that the derivatives may be applied to infection by
Enterococcus faecalis, although this needs further testing with
more clinical strains. In the derivatives containing a substituent
on the phenyl ring, such as H5-23 (MIC = 1.56 µM) and H5-
25 (MIC = 1.56 µM) with a 4-Cl substituent, H5-24 with a 4-
methoxy substituent (MIC = 1.56 µM) presented a much more
potent anti-bacterial activity than the leading compound 5. H5-
25 and H5-33, without the ester moiety on the 6 position of
the core ring, showed the same anti-bacterial activity as H5-23
and H5-32, which revealed that the removal of the ester did not
decrease the anti-bacterial activity. Moreover, the substitution
site of the carboxyl group on the side chain may decrease the
anti-bacterial activity (H5-23 vs. H5-34). Furthermore, compared
with theMBCs of H5-32 andH5-33, removing the ester increased
the bactericidal activity by eight times.
Bacteria within a biofilm can be 100–1,000 times more
resistant to antibiotics than corresponding planktonic cells
(Imaizumi et al., 2003). All the seven derivatives exhibited
bactericidal activities against S. epidermidis cells in mature
biofilms, especially the four derivatives H5-23, H5-24, H5-
33, and H5-35, which significantly decreased cell viability in
mature biofilms to 85.7, 77.5, 88.4, and 71.7%, respectively,
at concentrations of 4×MIC; compared to 128 µg/ml of
vancomycin treatment, which only reduced S. epidermidis living
cells in the mature biofilm by 11.4% (Liu et al., 2014). We
chose one strong biofilm-forming strain of MRSA (strain 226)
and tested the anti-biofilm activities of the four derivatives (H5-
32, H5-33, H5-34, and H5-35) by microtiter plate assay. All
derivatives showed biofilm-killing effects on 6 h young biofilms of
S. aureus, and the minimal biofilm-killing concentration was 200
µM. The anti-biofilm activities of these YycGHK inhibitors need
to be tested against more S. aureus strains in future studies. The
seven derivatives inhibited autophosphorylation of YycG, with
IC50 values ranging from 61.94 to 83.91 µM. This was suggestive
that the derivatives may elicit their anti-bacterial and anti-biofilm
effect through inhibiting the enzyme activity of the HK domain of
YycG, which is an important TCS that positively regulates biofilm
formation. To clarify whether the YycG inhibitors target other
HKs, we cloned and expressed HisKA and HATPase_c domains
of S. epidermidis ArlS (designated as ArlS’), which are similar
to those of YycG′ (as shown in Supplementary Figure 1). The
effects of the four derivatives (H5-32, H5-33, H5-34, and H5-
35) on the autophosphorylation of ArlS’ were determined by
using a Kinase-GloTM Luminescent Kinase Assay. None of them
showed an inhibitory effect on the autophosphorylation of ArlS’,
even at the highest concentration (200 µM; see Supplementary
Table 2 in the supplemental material). This was suggestive that
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the derivatives had a certain degree of specificity dependent on
the characteristics of the HATPase_c domain structure of the
different HKs. In addition, the derivatives showed low toxicity to
mammalian cells and healthy human erythrocytes at the highest
concentration (200 µM).
S. epidermidis is an opportunistic pathogen causing infections
of implanted medical devices, primarily due to its ability to
colonize and form biofilms on inert surfaces, which subsequently
act as a nidus for systemic dissemination (Wang et al., 2011).
The fluid dynamics of blood flow exert substantial shear forces
around the indwelling devices and influence biofilm formation
(Lam et al., 2014). To simulate the fluid dynamics of the in vivo
milieu, a flow-based live cell imaging system, BioFlux 1,000, was
used for developing biofilms. Four derivatives (H5-32, H5-33,
H5-34, and H5-35) were selected and incubated with bacteria at
a shear setting of 0.15 dyn/cm2 for 16 h. All of them strongly
inhibited biofilm formation under conditions of shear forces,
which was suggestive that the derivatives of compound 5 were
suitable candidates for the prevention of biofilm formation on
implanted medical devices.
In the present study, the seven newly designed derivatives with
intact thiazolopyrimidinone core structures, displayed higher
anti-bacterial and anti-biofilm activities than that of leading
compound 5. However, two derivatives, H5-34 and H5-35,
showed limited aqueous solubility characteristics at the highest
concentration (200 µM) and precipitated after incubation at
37◦C for 12 h, which may hinder these derivatives as drug
candidates for subsequent clinical steps. The derivatives will
need further modifying to improve the thiazole compounds’
drug-like properties (including higher aqueous solubility and
permeability, and lower toxicity), increasing their strong anti-
biofilm properties for eradicating biofilm-associated infections
and multidrug-resistant bacterial infections.
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